Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study

Abstract

BackgroundIncreased cortisol levels and genetic polymorphisms have been related to both major depressive disorder and antidepressant treatment outcome. The aim of this study is to evaluate the relationship between circadian salivary cortisol levels, cortisol suppression by dexamethasone and genetic polymorphisms in some HPA axis-related genes to the response to placebo and fluoxetine in depressed patients.MethodsThe diagnosis and severity of depression were performed using the Mini International Neuropsychiatric Interview (M.I.N.I.) and Hamilton depression scale (HAM-D17), respectively. Euthyroid patients were treated with placebo (one week) followed by fluoxetine (20 mg) (two months). Severity of depression was re-evaluated after placebo, three weeks and two months of fluoxetine treatments. Placebo response was defined as HAM-D17 score reductions of at least 25% and to < 15. Early response and response were reductions of at least 50% after three weeks and two months, and remission with ≤ 7 after two months. Plasma TSH, free-T4, circadian salivary cortisol levels and cortisol suppression by dexamethasone were evaluated. Seven genetic polymorphisms located in the Corticotrophin-releasing-hormone-receptor-1 (rs242939, rs242941, rs1876828), Corticotrophin-releasing-hormone-receptor-2 (rs2270007), Glucocorticoid-receptor (rs41423247), FK506-binding-protein-5 (rs1360780), and Arginine-vasopressin (rs3729965) genes were determined. Association analyses between response to placebo/fluoxetine and polymorphism were performed by chi-square or Fisher exact test. Cortisol levels were compared by t-test, ANOVA and the general linear model for repeated measures.Results208 depressed patients were recruited, 187 of whom were euthyroid. Placebo responders, fluoxetine responders and remitters exhibited significantly lower circadian cortisol levels than those who did not respond (p-values of 0.014, 0.008 and 0.021 respectively). Patients who abandoned treatment before the third week also exhibited a trend to low cortisol levels (p = 0.057). The polymorphisms rs242939 (CRHR1) and rs2270007 (CRHR2) were not in Hardy-Weinberg equilibrium. Only the rs242939 polymorphism (CRHR1) exhibited association with early response (three weeks) to fluoxetine (p-value = 0.043). No other association between outcomes and polymorphisms was observed.ConclusionsThese results support the clinical relevance of low salivary cortisol levels as a predictor of antidepressant response, either to placebo or to fluoxetine. Only one polymorphism in the CRHR1 gene was associated with the early response. Other factors may be involved in antidepressant response, although further studies are needed to identify them.Electronic supplementary materialThe online version of this article (doi:10.1186/s12888-014-0220-0) contains supplementary material, which is available to authorized users.

Don’t stress about CRF: assessing the translational failures of CRF1antagonists

“…CRF 1 system. Additionally, many genetic variant studies failed to replicate (Buttenschøn et al 2016, Ventura-Juncá et al 2014) or have not yet been replicated. Finally, the finding that variants of CRHBP and CRHR2 have been associated with psychiatric and stress-related disease lends support to the hypothesis that other components of the CRF system may be involved and warrants further exploration of polymorphs of CRHBP , CRHR2 , and/or RAMP2.…”

Salivary cortisol in post-traumatic stress disorder: a systematic review and meta-analysis

“…It is the end product of the HPA axis in humans. When faced with stressors the body may produce a corresponding stress response [ 11 ]. At the same time the body may secrete large amounts of cortisol to inhibit stress response by metabolic action, which in turn restores the body back to its normal functionality [ 12 , 13 ].…”

Low dose of caffeine enhances the efficacy of antidepressants in major depressive disorder and the underlying neural substrates

“…Psychosocial stress in humans leads to elevated cortisol levels via activation of the HPA axis . Depressed patients who subjected to antidepressant fluoxetine treatment exhibited a trend to low cortisol levels, suggesting the possible relevance of cortisol levels in the response of depressed patients to placebo or fluoxetine treatment . The treatment delay (from weeks to months) and inevitable side effects (aversive behavior such as suicide) are major limitations of current depression interventions .…”